Bkemv (Eculizumab-aee)

Bkemv (eculizumab-aeeb) is a complement inhibitor used for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis and atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

Limitation of Use: This therapeutic drug is not for the treatment of patients with Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). 

Recommended Dosage: 

Recommended Dosage Regimen for PNH: For patients aged 18 years and older, Bkemv treatment consists of:

• 600 mg weekly for the initial 4 weeks, followed by
• 900 mg for the fifth dose 1 week later, then
• 900 mg every 2 weeks thereafter. 

Recommended Dosage Regimen for aHUS: For patients aged 18 years and older, Bkemv treatment consists of:

• 900 mg weekly for the initial 4 weeks, followed by
• 1200 mg for the fifth dose 1 week later, then
• 1200 mg every 2 weeks thereafter. 

Note: For patients aged less than 18 years, administer this therapeutic drug based on body weight.

• Patients treated with Bkemv 300 mg/30 mL are at increased risk for serious meningococcal infections. It is crucial to vaccinate patients against meningococcal infections at least two weeks before initiating therapy unless the risks of delaying treatment outweigh the risks of infection. Monitor patients for early signs of meningococcal infections and advise them to seek immediate medical attention if they experience symptoms such as headache, fever, or stiff neck.
• Treatment with Eculizumab-aeeb can increase susceptibility to infections. It is crucial to monitor patients for signs of infection, including common and opportunistic infections. Prompt diagnosis and treatment are necessary if an infection is suspected. Patients should be educated on recognizing the symptoms of infection and the importance of reporting them promptly.
• In addition to meningococcal infections, patients receiving eculizumab-aeeb injections may be at higher risk for other bacterial, viral, and fungal infections. Continuous vigilance and preventive measures, such as vaccinations and prophylactic treatments, should be considered based on the patient’s overall health status and immunization history.
• Serious hypersensitivity reactions, including anaphylaxis, have been reported with eculizumab-aeeb 300 mg/30 mL. If a hypersensitivity reaction occurs, discontinue the infusion immediately and initiate appropriate medical treatment. Patients should be monitored closely during and after the infusion for any signs of hypersensitivity.
• Infusion reactions may occur during the administration of eculizumab-aeeb. These reactions can include fever, chills, and hypertension. Patients should be monitored during the infusion, and supportive measures should be available to manage any adverse reactions that may arise.
• Patients with existing chronic infections or underlying immune system disorders should be treated with caution. The potential benefits of eculizumab-aeeb must be weighed against the increased risk of exacerbating these conditions. Regular monitoring and appropriate management strategies should be implemented to mitigate risks.

What documents are required to import BKEMV to India?

BKEMV (eculizumab-aeeb) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order be confirmed?

• The order will be confirmed only after the receipt of:
• A valid prescription from the Doctor
• Import permit if applicable

Is BKEMV available in India?

BKEMV (eculizumab-aeeb injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Bkemv in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

BKEMV can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of BKEMV (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Bkemv 300 mg/30 mL price in India. 

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

What is the Generic Name for the trade name drug Bkemv®?

Eculizumab-aeeb is a Generic Name for the trade name drug Bkemv®.

What is the Manufacturer’s Name of Bkemv®?

Bkemv® is manufactured by Amgen Inc. 

Is Bkemv® approved by the FDA?

Yes, Bkemv® is approved by the FDA. Date of first approval: May 28, 2024.

What is the dosage and form of Bkemv® supplied?

Bkemv® is supplied as Injections: 300 mg/30 mL (10 mg/mL) in a single-dose vial for intravenous use. 

What are the most common side effects of Bkemv®? 

The most common side effects of Bkemv® in patients with PNH are nasopharyngitis, headache, back pain, and nausea. The most common side effects in patients with aHUS are headache, abdominal pain, diarrhea, hypertension, upper respiratory infection, vomiting, nasopharyngitis, anemia, urinary tract infections, cough, peripheral edema, nausea, and pyrexia.

How much does Bkemv® cost in India?

Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on the cost of Bkemv 300 mg/30 mL in India, it is recommended to Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Bkemv®?

Store Bkemv (eculizumab-aeeb) in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze.

Is it safe to buy Bkemv® online in India?

Yes, one can buy Bkemv online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in the country. We can help facilitate the supply of Bkemv® through legal channels.